Ardelyx steps up with a better round of PhIII data to compare with rivals at Ironwood, Synergy
Ardelyx $ARDX is taking a second shot at making a badly needed good late-stage impression with their lead drug for irritable bowel syndrome with constipation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
